Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer.
It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3.
A bi specific delta-like ligaand-3-directed T cell engager immunotherapy.
A monoclonal antibody, Type Bi-specific T-cell engager
Routes of administration Intravenous.
The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.
Considered it to be a first-in-class medication.
Tarlatamab is indicated for the treatment of adults with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.
The prescribing information includes a boxed warning for serious or life-threatening cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS).
The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.
The most common grade 3 or 4 laboratory abnormalities include decreased lymphocytes, decreased sodium, increased uric acid, decreased total neutrophils, decreased hemoglobin, increased activated partial thromboplastin time, and decreased potassium.
Treatment with tarlatamab lead to longer overall survival than chemotherapy among patients with small cell lung cancer whose disease has progressed during or after platinum base chemotherapy.